Perphenazine

Evidence Level: L5

Predicted Indications: 10

Perphenazine
Perphenazine: From Antipsychotic Therapy to Retinal Dystrophy with or without Extraocular Anomalies

## Pharmacist Assessment Report

Perphenazine: From Antipsychotic Therapy to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Perphenazine is a typical (first-generation) antipsychotic (phenothiazine class, D2/5-HT2A antagonist); this evidence pack does not document its originally approved indication (original_indications field empty, MOA marked as a data gap pending DrugBank confirmation). The TxGNN model’s top-ranked prediction is Retinal Dystrophy with or without Extraocular Anomalies, but on review this is supported by 0 clinical trials and 15 publications, none of which mention perphenazine — the evidence pack’s own analysis flags this as likely knowledge-graph noise rather than a genuine signal.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (original_indications empty; TFDA label extraction pending — DG001)
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.96% (raw rank 825)
Evidence Level	L5
UK Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for perphenazine is not available in this pack (DG002, MOA marked as data gap). Based on information embedded elsewhere in this evidence pack (see the anxiety-disorder candidate’s rationale), perphenazine is understood to act as a D2/5-HT2A receptor antagonist with additional H1/α1-adrenergic antagonism — consistent with its known use as a typical antipsychotic/phenothiazine. No original indication text was supplied, so the drug’s approved therapeutic history cannot be independently verified here.

There is no biologically plausible relationship between this mechanism and retinal dystrophy with or without extraocular anomalies, which is predominantly a group of inherited disorders caused by photoreceptor or retinal-pigment-epithelium gene defects. The evidence pack’s own mechanistic assessment reaches the same conclusion: it explicitly states there is “no known mechanistic link” between the two.

Having reviewed all 15 associated publications, none reference perphenazine, its pharmacological class, or any drug treatment for the ophthalmological conditions discussed — they cover orbital infections, diplopia, congenital ptosis, lens anomalies, cryptophthalmia, and related structural eye disorders. This pattern is best interpreted as keyword co-occurrence noise in the underlying knowledge graph rather than substantive biological evidence, despite the high TxGNN confidence score.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Note: none of the citations below mention perphenazine or its pharmacological class directly. They are general ophthalmology literature that co-occurs with the predicted disease term in the knowledge graph and are presented here for transparency, not as supporting evidence — consistent with the “Hold” recommendation above.

PMID	Year	Type	Journal	Key Findings
9416661	1997	Review	Semin Ultrasound CT MR	Orbital infections secondary to sinusitis; no drug treatment discussion relevant to perphenazine
20127583	2010	Review	Semin Neurol	Diagnostic approach to diplopia; not disease- or drug-specific
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis pathophysiology and evaluation
38249493	2023	Review	Taiwan J Ophthalmol	Congenital anomalies of lens shape and associated syndromes
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler vitreoretinal degeneration syndrome complex
38321238	2024	Review	Pediatr Radiol	Imaging features of pediatric ocular pathologies (congenital/developmental)
19064847	2008	Review	Arch Ophthalmol	Clinical features and management of orbital arteriovenous malformations
109006	1979	Case Report	Am J Ophthalmol	Unilateral cryptophthalmia case series
24413161	2014	Case Report	J Neuroophthalmol	Congenital trochlear-oculomotor synkinesis case
19826317	2009	Case Report	Optom Vis Sci	Congenital extraocular muscle fibrosis with variable synergistic divergence

UK Market Information

Perphenazine currently holds no UK marketing authorisations in this evidence pack (market_status: Not Marketed, total_licenses: 0). No product-level licence data is available to summarise in this report.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

(Key warnings, contraindications, and drug-interaction data in this evidence pack are all marked as data gaps or “not found” — DG001 remains a blocking gap for any formal safety screening.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction for perphenazine (retinal dystrophy with or without extraocular anomalies) has no supporting clinical trials, no mechanistically relevant literature, and the evidence pack’s own analysis identifies it as likely computational noise rather than a genuine signal (Evidence Level L5).

To proceed, the following is needed:

Resolve DG001 (TFDA/MHRA label warnings and contraindications) — currently blocking any S1 safety screening
Resolve DG002 (confirm mechanism of action via DrugBank API)
Obtain documented original indication data for perphenazine to enable a proper original-vs-predicted indication comparison
Separately note: this evidence pack also contains a materially stronger candidate — anxiety disorder (rank 10, Evidence Level L2, two clinical trials, 20 publications including several historical RCTs of perphenazine combinations) — which is rated “Proceed with Guardrails” and warrants its own dedicated evaluation report rather than being assessed alongside this Hold-rated candidate.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.